NRSN

NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. (NRSN) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 44.4, with 0/3 trend checks passing.

Price

$0.72

2026-07-16

Trend score

0/3

Downtrend

RSI (14)

44.4

Neutral

✕Price above MA50✕Price above MA200✕MA50 above MA200

Change stock

Search another ticker to view its stock analysis page.

Chart View

NRSN with MA50 and MA200

Dashboard News TradingView

NRSN • 2025-07-31 → 2026-07-15

PriceMA50MA200

Technical Indicators

Key levels & signals

MA50

$0.78-7.90% vs price

MA200

$0.91-20.61% vs price

RSI (14)

44.4Neutral zone

MACD Signal

MixedMACD near signal line

Macro Support

$0.67–$0.685.4% below price · 3 touches

Support Quality

3 touches0.6× zone volume

Chart Summary

Trend summary for NRSN

NeuroSense Therapeutics Ltd. (NRSN) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $0.72, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 7.9% and below the 200-day moving average by 20.6%.

Momentum and stretch context

NRSN currently has an RSI reading of 44.4, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.

What traders may watch next

For traders reviewing NRSN next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.

Company profile

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.

Sector

Healthcare

Industry

Biotechnology

CEO

Alon Ben-Noon

Employees

Market cap

$17.7M

Beta

1.56

52-week range